Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of$0.04 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this drugmaker would post a loss of $0.03 per share when it actually produced a loss of$0.02, delivering a surprise of +33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Geron, which belongs to the Zacks Medical - Bi ...